

## DISCUSSION

ALL is one of the most frequent childhood diseases in which there is malignant clonal proliferation of the progenitor lymphoid cells in the BM, with blocked differentiation at an early stage as a consequence of somatic mutations. These abnormal cells accumulate, supersede normal hematopoietic precursors, disrupt the normal BM cell distribution and finally appear in peripheral blood and they are capable of infiltration of extramedullary sites with disease progression. Moreover, ALL is a biologically heterogeneous disorder so that morphologic, immunologic, cytogenetic, biochemical, and molecular genetic characterizations of leukemia lymphoblasts are required to establish the diagnosis or to exclude other possible causes of BM failure and to classify ALL subtypes. This heterogeneity reflects the fact that leukemia may develop at any point of the multiple stages of normal lymphoid differentiation<sup>(32,119)</sup>. ALL can be classified into 4 groups: Pro-B-ALL, common B-ALL, pre-B-ALL and mature B-ALL<sup>(120)</sup>. B-ALL forms the majority of ALLs in children<sup>(121)</sup>. It represents 75% of all acute leukemias, with a peak incidence at 2 to 5 years of age<sup>(122)</sup>.

Independent of the classical prognostic indicators like age, WBC count, immunophenotype, cytogenetic analysis and treatment response; MRD detected in early phases of therapy is shown to provide powerful prognostic information<sup>(82)</sup>. MRD corresponds to the very low number of cells remaining in the patient during or after the treatment; namely in the remission period and is not detectable by morphologic examination<sup>(77)</sup>. The morphologic threshold for unequivocal detection of residual disease in patients with precursor B-ALL is generally considered to be a blast count of 5% of total nucleated cells in bone marrow aspirate smears<sup>(59)</sup>.

Flow cytometry is a rapid, convenient and generally applicable technique for detecting MRD in precursor B-ALL. It can be more than 100 times more sensitive than morphologic examination<sup>(79-81)</sup>. It is also used to differentiate lymphoblasts from their normal immature B-lineage counterparts, termed hematogones, due to the fact that they share morphologic and immunophenotypic features in particular the expression of CD10, CD34 and TdT, which could hamper MRD assessment in the regenerating phase occurring during chemotherapy and after treatment withdrawal, when normal precursors often expand<sup>(92,123)</sup>. The combination CD34/CD19/TdT/CD10 and CD38 is commonly used to differentiate these cell types, based on the difference in fluorescence intensity displayed by both. However, the immunophenotypic differences between hematogones and leukemic blasts in some cases may be subtle and extensive experience may be required for reliable interpretation of some antigens or for detecting very low level of disease<sup>(93)</sup>.

MRD detection by flow cytometry depends on the presence of leukemia associated immunophenotype, which is based on the detection of aberrant expression of a number of antigens on lymphoblasts. This is very important especially in cases of common B-ALL (CD10+ve), in which there is major difficulty to differentiate blast cells from hematogones<sup>(59)</sup>.

Studies to differentiate hematogones from blasts gained importance in recent years. However, because of the absence of specific and informative markers, normal lymphoid progenitors may be misinterpreted as MRD and the accuracy and reliability of FC-based

MRD measurement may be limited at BM regeneration phase<sup>(124)</sup>. The ideal FC marker for MRD detection in precursor B-ALL should show a consistent pattern of expression in hematogones and an aberrant expression pattern in leukemic cells in a high proportion of cases. There should be minimal overlap in expression between benign and leukemic cells and the level of expression in leukemic cells should be stable over time<sup>(93)</sup>.

CD81 is an integral surface membrane protein that is a member of the tetraspanin family. In humans, CD81 is expressed in most tissues, including blood cells with the exception of erythrocytes and platelets<sup>(110)</sup>. CD81 forms a CD19-CD21-CD81 multi-molecular complex that is involved in signal transduction in B-cells<sup>(95, 96, 125)</sup>.

The aim of the present work was to study the expression of CD81 on leukemic blast cells of pediatric precursor B-ALL as compared to benign precursor B-cells (hematogones) and to evaluate its utility in the detection of minimal residual disease by FC (as extensive data regarding the use of this marker in MRD detection were not present in literature).

The current study was conducted on a total of 64 patients divided in to two groups. The first group included 32 patients diagnosed as precursor B -ALL, monitored at diagnosis and on day 28 after induction chemotherapy. Their ages ranged from 0.5 to 16 years with a median of 5 years and a male to female ratio of 1.2:1. The second group included 32 age and sex matched patients doing bone marrow aspiration for conditions other than hematological malignancies, whose bone marrows showed increased hematogones (ITP, postchemotherapy neuroblastoma and castleman's disease), which were confirmed by FC as controls. Moreno-madrid et al.<sup>(126)</sup> studied the presence of hematogones in the bone marrow of pediatric patients and defined them immunophenotypically by co-expression of CD10, CD38 and CD19 and by non-expression of surface immunoglobulins, these findings were consistent with our results. Moreover, they stated that hematogones were found in small concentrations in healthy people but their numbers were increased among children or adults undergoing various pathological processes as lymphomas, non neoplastic blood cytopenias, post-chemotherapy, post bone marrow transplant and HIV, being the most common in such situations<sup>(92, 127)</sup>, which explained and confirmed why we chose such population as control group.

As regards the hematological findings, serum LDH levels and uric acid levels in the present study, B-ALL cases at diagnosis showed a statistically significant difference ( $p < 0.001$ ) from the control group and from day 28 follow up BM specimens. This was attributed to adequate response to induction chemotherapy and a reduction in the tumor burden. Similarly, Hafiz et al.<sup>(128)</sup> and Fawzi et al.<sup>(129)</sup>, found a statistically significant difference ( $p < 0.001$ ) between B-ALL cases at diagnosis and both the control group and follow up day 28 post-induction chemotherapy specimens, as regards their hematological findings and LDH levels. They also attributed that to effective induction chemotherapy and reduction in the tumor burden.

Immunophenotypically, common precursor B-ALL was the most commonly encountered subtype in our study constituting 50% of the cases followed by pre-B-ALL (31.3%) and the least frequently encountered subtype was pro-B-ALL (18.8%). Wenxiu et al.<sup>(130)</sup> stated that the most commonly encountered subtype in their study was also the common B-ALL subtype.

Regarding CD81 expression, we found that CD81 MFI was lower in leukemic blast cells of B-ALL cases than in hematogones of the control group, with a mean of  $304.49 \pm 202.18$  and  $2684 \pm 502.1$  respectively and the difference between them was statistically significant ( $p < 0.001$ ). Follow up BM specimens of all studied B-ALL cases based on the routine MRD panel were negative for residual B-ALL blasts and the TdT+/CD10+/CD19+ cells in these specimens were benign hematogones, which also showed bright CD81 expression with a mean of  $2434.11 \pm 309.16$ , like that of control specimens. This confirmed that CD81 showed bright expression on hematogones. We also screened CD81 expression on normal BM cells and found that hematogones had the brightest expression while lymphocytes, myeloid blasts and monocytes had moderate to weak expression and granulocytes had the weakest expression level of CD81.

In agreement with our findings were the findings reported by Muzzafar et al. <sup>(93)</sup> who studied the expression of CD81 by FC on benign precursor B-cells (hematogones) and leukemic blasts in precursor B-ALL and established its usefulness in MRD assays. They found that hematogones showed the brightest CD81 expression and leukemic blasts showed aberrantly decreased expression of CD81 and the difference between the range of MFI of immature hematogones and the range of MFI of leukemic blasts was statistically significant ( $P < 0.0034$ ). Moreover, they also mentioned that in cases which were negative for MRD benign immature hematogones showed bright CD81 expression. They also found similar findings to ours when they studied CD81 expression among normal BM cells.

Barrena et al. <sup>(131)</sup> characterized CD81 expression during normal B-cell maturation and in a variety of B-lineage neoplasms as part of a broader study of tetraspanin molecule expression in benign and neoplastic B-cells. They demonstrated uniformly high levels of CD81 expression in early stage CD34+/CD10+ and late stage CD34-/CD10+ hematogones. Moreover, CD81 was aberrantly underexpressed in nine (75%) out of twelve precursor B-ALL cases in their series.

Luo et al. <sup>(103)</sup> reported that FC of BM lymphoid cells showed that early B-cell progenitors expressed the highest level of CD81 and confirmed the lack of CD81 expression in other hematopoietic precursors which was consistent with our findings. They also mentioned that the differential expression of CD81 in lymphoid cell types in the bone marrow could potentially be exploited for diagnostic purposes in separating lymphoid from non-lymphoid acute and chronic leukemias and that this separation may be particularly useful in minimally differentiated leukemias, where other known immunophenotypic markers or cytogenetic abnormalities may be lacking.

In this context Muzzafar et al. <sup>(93)</sup> added that the explanation of aberrant CD81 underexpression in precursor B-ALL is still unknown. However, they suggested that the partially decreased CD81 expression in precursor B-ALL could affect CD19 signaling and/or the adhesion of leukemic blasts to the BM microenvironment.

The utility of tetraspanin molecules including CD81 in combination with other B-cell associated markers, not only for the diagnostic classification of B-cell neoplasias but also for the identification of aberrant phenotypes that could be used for monitoring of minimal disease levels, was also reported in several other studies (Sanchez et al, Lucio et al, Vidriales et al) <sup>(132-134)</sup>.

As regards CD81 expression in other neoplastic hematological conditions, Luo et al.<sup>(103)</sup> reported that high levels of CD81 expression by FC was seen in diffuse large B-cell lymphoma (DLBCL) cases and in normal germinal centre B-cells, that could be used in the future in the risk stratification of these cases. In contrast, FC of plasma cell myeloma showed diminished expression of CD81 in myeloma cells. Zoller et al.<sup>(95)</sup> also mentioned that in some carcinomas, CD81 appeared to have anti-metastatic effects.

We further studied CD81 expression among different immunologic subtypes of B-ALL. We found that CD81 MFI was lowest in common B-ALL (with a mean of  $243.80 \pm 119.77$ ) followed by pre-B-ALL (with a mean of  $263.90 \pm 104.78$ ) and it was highest in pro-B-ALL (with a mean of  $534.0 \pm 335.17$ ). There was a statistically significant difference between pro-B-ALL and common B-ALL ( $p=0.002$ ) and between pro-B-ALL and pre-B-ALL ( $p=0.005$ ). However, no statistically significant difference was found between common and pre-B-ALL. No definitive explanations were found for the different expression levels of CD81 among the different subtypes; however this could be attributed to the synergistic effect of CD81 with other markers.

We also found that CD81 MFI was lower among CD10 positive cases when compared to CD10 negative cases, with a mean of  $251.53 \pm 112.51$  and  $534.0 \pm 335.17$  respectively, however, the difference was not statistically significant. CD34 positive cases showed slightly higher CD81 MFI than CD34 negative cases, with a mean of  $307.36 \pm 220.02$  and  $294.26 \pm 131.93$  respectively, but the difference was also not statistically significant most likely owing to the relatively few samples studied.

In contrast to our findings Barrena et al.<sup>(131)</sup> reported that CD34 positive precursor B-ALL cases displayed a significantly reduced CD81 expression than CD34 negative cases. The discrepancy between our findings and that of Barrena et al. could be attributed to our small sample size.

In this context Muzzafar et al.<sup>(93)</sup> reported that the frequency of aberrantly decreased CD81 was higher among precursor B-ALL cases that were CD34 positive than among CD34 negative cases.

Luo et al.<sup>(103)</sup> measured CD81 and CD10 expression in cell suspensions from DLBCL tumor specimens by FC analysis and found that all tumor cells showed high levels of CD81 expression independent of the level of CD10 expression, although they mentioned that CD81 expression was regulated developmentally in a similar nature to CD10, being high in both early B-cell progenitors in the bone marrow and in the germinal center.

In the present work, two cases who were further followed up after day 28, revealed relapse after consolidation by routine FC analysis. On performing CD81, BM leukemic blasts revealed dim expression of CD81 (similar to that of the diagnostic specimens), which was confirmed by the conventional MRD panel, although the conventional morphological examination could not accurately specify that these cells were malignant blasts and not normal hematogones. This evidence highlights the specificity of CD81 in differentiation between normal hematogones and actual blast cells. The persistence of low CD81 MFI in these cases might reflect the stability of CD81 as a marker of neoplastic disease.

## Summary

---

This was in agreement with Muzzafar et al <sup>(93)</sup> who analyzed CD81 expression in residual blasts in de novo cases, relapsed cases and various cases at the end of induction, after consolidation as well as during maintenance chemotherapy and found that in nearly all cases, leukemic blasts retained their aberrantly decreased expression of CD81 at all stages of therapy, which showed that MFI of CD81 expression was stable in 91% of their cases with sequential sampling.

An interesting finding in one of these relapsed cases was showing positivity for NG2 marker, which is an established marker of disease aggressiveness and could explain the cause of this relapse.

That findings were important to mention as several other studies (Van Lochem et al, Van Wering et al, Borowitz et al, Chen et al. <sup>(135-138)</sup>) reported that phenotypic shifts are well known to occur in precursor B-ALL with some markers between diagnostic and post-chemotherapy or relapse specimens on leukemic blasts and on background hematogones in up to 72% of cases.

One case was unexpectedly found to have high CD81 MFI at diagnosis (MFI=1304), it was thus decided not to include this case in the analysis in order not to disturb the homogeneity of our sample, but this case was thoroughly investigated and had no remarkable clinical or hematological findings. On immunophenotyping this case showed common B-ALL phenotype with aberrant expression of CD5 and was CD34 negative. However, this case died before ending the induction therapy so we weren't capable of follow up on day 28 post-induction chemotherapy. No definitive explanation could be found for this high CD81 MFI. However, this needs to be thoroughly investigated on a larger sample size to find out a definitive explanation for this result. In this context muzzafar et al. <sup>(93)</sup> reported that five cases had unexpectedly high CD81 MFI and three of them were negative for CD34.

In the present study there was no correlation between CD81 MFI on blast cells and different studied hematological parameters; as WBC count at diagnosis, blast counts in the peripheral blood or in the bone marrow. Although no data concerning the correlation of CD81 MFI on blast cells with any of these hematological parameters were found in literature, we could attribute these findings to the relatively few samples studied.

To improve the diagnostic utility of CD81 as a marker for MRD detection, we tried to establish a lower threshold for CD81 expression by hematogones, using ROC curve analysis. A value of 1134 for CD81 MFI was shown to have highest sensitivity and specificity for separation between leukemic blasts and hematogones, where hematogones had values greater than 1134; while blasts had values lower than or equal to 1134. This cutoff value in the present study was close to that established by Muzzafar et al <sup>(93)</sup>. Who established a cutoff value for CD81 MFI, in which blast cells of most cases had values equal to or less than 1000 and hematogones had values more than 1000. The results of ROC curve analysis in the present study can't be generalized, due to the insufficient sample size used and also because the random sampling method was not applied.

The results of the current study together with those of other relevant studies indicated that CD81 could be a robust marker for differentiating leukemic blast cells in precursor B-ALL from hematogones and could be a useful addition to the flow cytometric panels used for MRD assessment.

## SUMMARY

Acute lymphoblastic leukemia (ALL) is a malignant clonal disorder which originates in a single B- or T-lymphocyte progenitor cell. This results in proliferation and accumulation of blast cells in the bone marrow (BM), which suppress hematopoiesis and disrupts the normal BM cell distribution, then appears in the peripheral blood. ALL represents approximately 80% of childhood leukemias among which precursor B-ALL represents 85%. ALL shows a sharp peak among children aged from 2 to 5 years with slight male predominance.

Conventional methods for diagnosis of ALL include mainly peripheral blood and BM examination together with immunophenotyping by flow cytometry. In addition to diagnosis, flow cytometric immunophenotyping (FCI) is used in minimal residual disease (MRD) detection as it is rapid, relatively sensitive and quantitative. MRD is defined as the lowest detectable level of disease in patients in complete clinical remission which can only be detected by highly sensitive techniques such as multi-parametric flow cytometry or PCR. MRD is considered the major predictor for relapse of leukemia. Evaluation of MRD can be problematic in conditions where hematogones are abundant in the BM; this is frequently seen in BM specimens of children after therapy of ALL. This difficulty originates from the close resemblance between hematogones and lymphoblasts as regards their morphological and immunophenotypic features.

Since leukemic blasts often show aberrant gain or loss of surface antigens or changes in the pattern or intensity of antigen expression giving rise to an immunophenotypic profile distinct from normal cells, the ideal FC marker for MRD detection should show a consistent pattern of expression on hematogones and an aberrant expression pattern on leukemic cells with minimal overlap in expression between both. In addition, the level of expression on leukemic cells should be stable over time.

CD81 known as TAPA-1, a member of the tetraspanin family, found on most human tissues except RBCs and platelets. It forms a CD19-CD21-CD81 multi-molecular complex that is involved in signal transduction in B-cells.

The aim of the present work was to study the expression of CD81 on leukemic blast cells of pediatric precursor B-ALL as compared to hematogones and to evaluate its utility in MRD detection by FC. The present study was conducted on a total of 64 patients divided into two groups. The first group included 32 patients diagnosed as precursor B-ALL, monitored at diagnosis and on day 28 after induction chemotherapy, while the second group included 32 age and sex matched patients doing BMA for conditions other than hematological malignancies; whose BMs showed increased hematogones, which was confirmed by FCI as controls. The selection of cases was based on their clinical features, morphology and immunophenotyping of the leukemic cells.

Analysis of CD81 expression by FCI was done for B-ALL patients at diagnosis and on day 28 post-induction to detect its usefulness in differentiating leukemic blasts from hematogones and in MRD detection. Moreover, its expression was compared among different subtypes of B-ALL, as well as for the control group.

## *Summary*

---

It was found that CD81 MFI was lower in leukemic blasts of B-ALL cases than in hematogones of control group ( $p < 0.001$ ). With exception of the two cases that died during the induction phase of chemotherapy, all cases entered in complete remission on day 28, showing negative MRD and most of them had increased hematogones by the routine MRD panel. This was confirmed by high MFI CD81 on day 28 post-induction chemotherapy specimens. Beyond day 28 two relapsed cases showed persistently low CD81 MFI that might indicate its stability on leukemic blasts after chemotherapy. A statistically significant difference in CD81 expression was found among different subtypes of B-ALL, in which common B-ALL showed the least expression. ROC curve analysis was performed in an attempt to establish lower threshold for CD81 expression by hematogones. A cutoff value of 1134 for CD81 MFI was found to have the highest sensitivity and specificity for separation between leukemic blast cells and hematogones, where leukemic blasts were  $\leq 1134$  and hematogones were  $> 1134$ .

Based on the results of the present study, it can be concluded that CD81 could be a robust marker for differentiating leukemic blast cells in precursor B-ALL from hematogones and a useful addition to the flow cytometric panels used for assessment of MRD.

## CONCLUSIONS

From the present study we can conclude the following:

1. CD81 expression was significantly lower on leukemic blast cells of precursor B-ALL cases than on hematogones, thus it could be a useful marker to differentiate between them.
2. CD81 expression was significantly lower in common and pre-B-ALL subtypes than in pro-B-ALL subtype, which may increase its value in differentiating between CD10+ve blasts and hematogones.
3. A cutoff value of 1134 for CD81 MFI was established to differentiate between leukemic blast cells and hematogones, where leukemic blasts were  $\leq 1134$  and hematogones were  $>1134$ .
4. Diminished CD81 expression is a sensitive marker for residual B-ALL. Thus, it could be a useful addition to flow cytometric panels used for assessment of minimal residual disease.
5. CD81 expression on blast cells of precursor B-ALL was stable with time and following chemotherapy, which adds to its usefulness in minimal residual disease detection.
6. No significant correlation was found between CD81 MFI and different studied hematological parameters.

## **RECOMMENDATIONS**

1. Addition of CD81 to the flow cytometric panel used for minimal residual disease detection in B-ALL.
2. Conducting larger studies for better assessment of CD81 expression on leukemic B-ALL blasts and hematogones and for better characterization of a cutoff value of CD81 expression that can accurately separate between them, so that it can be generalized to all B-ALL cases.
3. The use of fluorescent beads to standardize the fluorescent scale of the machine to be comparable with other laboratories.
4. Measurement of CD81 expression at several follow up points during and/or after chemotherapy for better assessment of its stability through time and with chemotherapy.

## REFERENCES

1. Kaushansky K, Lichtman MA, Beutler E. Acute lymphoblastic leukemia. In: Kaushansky K, Lichtman M, Beutler E, Kipps T, Prchal J, Seligsohn U (eds). Williams hematology. 8<sup>th</sup>ed. China: McGraw-Hill Companies; 2010. 1409-31.
2. Childhood Cancer Site. Childhood cancer: Sec. 28. In: Howlader N, Noone AM, Krapcho M (eds). SEER cancer statistics review 1975-2010. Bethesda: National Cancer Institute; 2013. 1-22.
3. Hodgson S, Foulkes W, Eng C, Maher E. A practical guide to human cancer genetics. 3<sup>rd</sup>ed. New York: Cambridge University Press; 2007.
4. Thomas X, Le QH. Prognostic factors in adult acute lymphoblastic leukemia. J Hematol 2003; 8:233-42.
5. Greaves MF. Infection, immune responses and the aetiology of childhood leukemia. Nat Rev Cancer 2006; 6:193-203.
6. Hjalgrim LL, Rostgaard K, Schmiegelow K, Soderhall S, Kolmannskog S, Vettenranta K, et al. Age and sex specific incidence of childhood leukemia by immunophenotype in the Nordic countries. J Natl Cancer Inst 2003; 95(20): 1539-44.
7. National Cancer Registry. Childhood cancer. Egypt: Ministry of Health and Population; 2010.
8. Cavdar A, Kutlux T. Childhood cancer. In: Freedman LS, Edwards BK, Ries LAG, Young JL (eds). Cancer incidence in four member countries (Cyprus, Egypt, Israel, and Jordan) of the Middle East Cancer Consortium (MECC) Compared with US SEER. Bethesda: National Cancer Institute; 2006. 142-50.
9. McNeil DE, Coté TR, Clegg L, Mauer A. SEER update of incidence and trends in pediatric malignancies: acute lymphoblastic leukemia. Med Pediatr Oncol 2002; 39: 554-7.
10. Greer PJ, Foerster J, Rodgers MG, Paraskevas F, Glader B, Arber AD, et al. Acute lymphoblastic leukemia in children. In: Greer JP, Foerster J, Rodgers GM, Paraskevas F, Glader B, Arber DA, et al (eds). Wintrobe's clinical hematology. 12<sup>th</sup>ed. Philadelphia: Lippincott Wilkins; 2009. 1890-917.
11. Dores GM, Devesa SS, Curtis RE, et al. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood 2012; 119: 34.

## References

---

12. Gurney JG, Bondy ML. Epidemiologic research methods and childhood cancer. In: Pizzo PA, Poplack DG (eds). Principles and practice of pediatric oncology. 4<sup>th</sup> ed. Philadelphia: Lippincott-Raven; 2002. 13-20.
13. Buffler PA, Kwan ML, Reynolds P, Urayama KY. Environmental and genetic risk factors for childhood leukemia: appraising the evidence. *Cancer Invest* 2005; 23:60-75.
14. Campana D, Pui CH. Childhood acute lymphoblastic leukemia In: Hoffbrand AV, Catovsky D, Tuddenham EGD, Green AR (eds). Postgraduate Haematology. 6<sup>th</sup> ed. USA: Blackwell Publishing Ltd; 2011. 448-60
15. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. *N Engl J Med* 2004; 350: 1535-48.
16. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. *Lancet* 2008; 371(9617): 1030-43.
17. Inaba H, Greaves M, Mullighan GC. Acute lymphoblastic leukemia. *Lancet* 2013; 381(9881): 1943-55
18. Lowe EJ, Pui CH, Hancock ML, Geiger TL, Khan RB, Sandlund JT. Early complications in children with acute lymphoblastic leukemia presenting with hyperleukocytosis. *Pediatr Blood Cancer* 2005; 45: 10-5.
19. Anghelescu DL, Burgoyne LL, Liu T, Li CS, Pui CH, Hudson MM, et al. Clinical and diagnostic imaging predict anesthetic complications in children presenting with malignant mediastinal masses. *Paediatr Anaesth* 2007; 17:1090-8.
20. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. The morphological classification of acute lymphoblastic leukaemia: concordance among observers and clinical correlations. *Br J Haematol* 1981; 47 (4): 553-61.
21. Ali N. Acute lymphoblastic leukemia: updates. *Hematology* 2010; 26: 41-4.
22. Bain BJ. Diagnosis and classification of acute leukemia. In: Hoffbrand A, Catovsky D, Tuddenham E (eds). Postgraduate haematology. 5<sup>th</sup> ed. Oxford: Blackwell Publishing Ltd; 2005. 476-91.
23. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pineda SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4<sup>th</sup> ed. Lyon, France: International Agency for Research on Cancer Press; 2008.
24. Naeim F. Principles of immunophenotyping. In; Grody WW, Rao PN, Naeim F (eds). Hematopathology: morphology, immunophenotype, cytogenetics and molecular approaches. 1<sup>st</sup> ed. USA: Elsevier Academic Press; 2008. 27-57.

## References

---

25. Pui CH, Chessells JM, Camitta B, Baruchel A, Biondi A, Boyett JM, et al. Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. *Leukemia* 2003; 17 (4): 700-6.
26. Dakka N, Bellaoui H, Bouzid N, Khattab M, Bakri Y, Benjouad A. CD10 and CD34 expression in childhood acute lymphoblastic leukemia in Morocco: clinical relevance and outcome. *Pediatr Hematol Oncol* 2009; 26(4): 216-31.
27. Li ZG, Zhao W, Wu MY, Hu YM. Variant fusion transcript in ALL children with E2A-PBX1 fusion gene positive. *Zhongguo Shi Yan Xue Ye Xue Za Zhi* 2006; 14(3):516-20.
28. Jimenez-Morales S, Miranda-Peralta E, Saldana-Alvarez Y, Perez-Vera P, Paredes-Aguilera R, Rivera-Luna R, et al. BCR-ABL, ETV6-RUNX1 and E2A-PBX1: Prevalence of the most common acute lymphoblastic leukemia fusion genes in Mexican patients. *Leukemia Res* 2008; 32(10): 1518-22.
29. Iwamoto S, Deguchi T, Ohta H, Kiyokawa N, Tsurusawa M, Yamada T, et al. Flow cytometric analysis of de novo acute lymphoblastic leukemia in childhood: report from the Japanese Pediatric Leukemia/Lymphoma Study Group. *Int J Hematol* 2011; 94(2): 185-92.
30. McGregor S, McNeer J, Gurbuxani S. Beyond the 2008 World Health Organization classification: the role of the hematopathology laboratory in the diagnosis and management of acute lymphoblastic leukemia. *Semin Diagn Pathol* 2012; 29(1): 2-11.
31. Mullighan CG. The molecular genetic makeup of acute lymphoblastic leukemia. *Hematol Am Soc Hematol Educ Program* 2012; 2012: 389-96.
32. Conter V, Rizzari C, Sala A, Chiesa R, Citterio M, Biondi A. Acute lymphoblastic leukemia. *Orphanet Encyclopedia* 2004. Available from:  
<https://www.orpha.net/data/patho/Pro/en/AcuteLymphoblasticLeukemia-FRenPro3732.pdf>. [Accessed On: 5 Jan, 2015].
33. Moorman AV. The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemia. *Blood Rev* 2012; 26:123-35.
34. Paulsson K, Johansson B. High hyperdiploid childhood acute lymphoblastic leukemia. *Genes Chromosom Cancer* 2009; 48: 637-60.
35. Paulsson K, Forestier E, Lilljebjorn H, Heldrup J, Behrendtz M, Young BD, et al. Genetic landscape of high hyperdiploid childhood acute lymphoblastic leukemia. *Proc Natl Acad Sci USA* 2010; 107: 21719-24.

## References

---

36. Woo SJ, Alberti OM, Tirado AC. Childhood acute lymphoblastic leukemia. *Exp Hematol Oncol* 2014; 3: 1-14.
37. Moorman AV, Ensor HM, Richards SM, Chilton L, Schwab C, Kinsey SE, et al. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. *Lancet Oncol* 2010; 11: 429–38.
38. Forestier E, Heyman M, Andersen MK, Autio K, Blennow E, Borgstrom G, et al. Outcome of ETV6/RUNX1-positive childhood acute lymphoblastic leukaemia in the NOPHO-ALL-1992 protocol: frequent late relapses but good overall survival. *Br J Haematol* 2008; 140: 665–72.
39. Chessells JM, Harrison CJ, Kempinski H, Webb DK, Wheatley K, Hann IM, et al. Clinical features, cytogenetics and outcome in acute lymphoblastic and myeloid leukaemia of infancy: report from the MRC Childhood Leukaemia working party. *Leukemia* 2002; 16: 776–84.
40. Moorman AV, Raimondi SC, Pui CH, Baruchel A, Biondi A, Carroll AJ, et al. No prognostic effect of additional chromosomal abnormalities in children with acute lymphoblastic leukemia and 11q23 abnormalities. *Leukemia* 2005; 19: 557–63.
41. Biondi A, Cimino G, Pieters R, Pui CH. Biological and therapeutic aspects of infant leukemia. *Blood* 2000; 96: 24–33.
42. Ramakers-van Woerden NL, Beverloo HB, Veerman AJ, Camitta BM, Loonen AH, van Wering ER, et al. In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype. *Leukemia* 2004; 18: 521–9.
43. Schwartz S, Rieder H, Schläger B, Burmeister T, Fischer L, Thiel E. Expression of the human homologue of rat NG2 in adult acute lymphoblastic leukemia: close association with MLL rearrangement and a CD10(-)/CD24(-)/CD65s(+)/CD15(+) B-cell phenotype. *Leukemia* 2003; 17(8): 1589-95.
44. Dyer MJ, Akasaka T, Capasso M, Dusanjh P, Lee YF, Karran EL, et al. Immunoglobulin heavy chain locus chromosomal translocations in B-cell precursor acute lymphoblastic leukemia: rare clinical curios or potent genetic drivers?. *Blood* 2010; 115:1490–9.
45. Russell LJ, Capasso M, Vater I, Akasaka T, Bernard OA, Calasanz MJ, et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. *Blood* 2009; 114: 2688–98.

## References

---

46. Harewood L, Robinson H, Harris R, Al-Obaidi MJ, Jalali GR, Martineau M, et al. Amplification of AML1 on a duplicated chromosome 21 in acute lymphoblastic leukemia: a study of 20 cases. *Leukemia* 2003; 17: 547–53.
47. Soulier J, Trakhtenbrot L, Najfeld V, Lipton JM, Mathew S, Avet-Loiseau H, et al. Amplification of band q22 of chromosome 21, including AML1, in older children with acute lymphoblastic leukemia: an emerging molecular cytogenetic subgroup. *Leukemia* 2003; 17: 1679–82.
48. Rand V, Parker H, Russell LJ, Schwab C, Ensor H, Irving J, et al. Genomic characterization implicates iAMP21 as a likely primary genetic event in childhood B-cell precursor acute lymphoblastic leukemia. *Blood* 2011; 117: 6848–55.
49. Naeim F, Rao PN, Grody WW. The neoplasms of precursor lymphoblasts. In: Grody WW, Rao PN, Naeim F (eds). *Hematopathology: morphology, immunophenotype, cytogenetics and molecular approaches*. 1<sup>st</sup> ed. USA: Elsevier Academic Press; 2008. 257-78.
50. Margolin JF, Steuber CP, Poplack DG. Acute lymphoblastic leukemia. In: Pizzo PA, Poplack DG (eds). *Principles and practice of pediatric oncology*. 4<sup>th</sup>ed. Philadelphia: Lippincott-Raven; 2001. 489-544.
51. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. 1<sup>st</sup>ed. Lyon: IARC Press; 2001.
52. Abitar M, Giles JF, Kantarjian H. Diagnosis of acute lymphoblastic leukemia. In: Estey EH, Faderl SH, Kantarjian HM (eds). *Acute leukemias*. Berlin: Hematological Malignancies; 2008. 119-130.
53. Larson AR, Anastasi J. Acute lymphoblastic leukemia: clinical presentation, diagnosis and classification. In: Estey EH, Faderl SH, Kantarjian HM (eds). *Acute leukemias*. Berlin: Hematological Malignancies; 2008. 109-118.
54. Hoelzer D, Gokbuget N. Adult acute lymphoblastic leukemia. In: Hoffbrand A, Catovsky D, Tuddenham E (eds). *Postgraduate haematology*. 5<sup>th</sup>ed. Oxford: Blackwell Publishing Ltd; 2005. 525-41.
55. Le Beau MM, Larson RA. Cytogenetics and neoplasia. In: Hoffman R, Benz EJ, Shattil SJ (eds) *Hematology: basic principles and practice*. 3<sup>rd</sup>ed. London: Churchill Livingstone; 2000. 848–69.
56. Rao PN. Principle of cytogenetics. In: Grody WW, Rao PN, Naeim F (eds). *Hematopathology: morphology, immunophenotype, cytogenetics and molecular approaches*. 1<sup>st</sup> ed. Philadelphia: Elsevier; 2008. 57-65.

## References

---

57. Wolff DJ, Bagg A, Cooley LD, Dewald GW, Hirsch BA, Jacky PB, et al. Guidance for fluorescence in situ hybridization testing in hematologic disorders. *J Mol Diagn* 2007; 9(2):134-43.
58. Craig FE, Ohorio P, Gorrill TS, Swerdlow SH. Flow cytometric immunophenotyping of cerebrospinal fluid specimens. *Am J Clin Pathol* 2011; 135:22-34.
59. Adin-Cinar S, Kucuksezer UC, Deniz G. Implications of minimal residual disease by flow cytometry in pediatric acute leukemia. *Int Trends Immun* 2013; 1(4):54-61.
60. Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. *J Clin Oncol* 1996; 14 (1): 18-24.
61. Schultz KR, Pullen DJ, Sather HN, Shuster JJ, Devidas M, Borowitz MJ, et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). *Blood* 2007; 109(3): 926-35.
62. Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grümayer R, Möricke A, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. *Blood* 2010; 115 (16): 3206-14.
63. Rives S, Estella J, Gómez P, López-Duarte M, de Miguel PG, Verdeguer A, et al. Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation improves early outcome in paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL): results of the Spanish Cooperative Group SHOP studies ALL-94, ALL-99 and ALL-2005. *Br J Haematol* 2011; 154:600-11.
64. Schultz KR, Bowman WP, Aledo A, Slayton WB, Sather H, Devidas M, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. *J Clin Oncol* 2009; 27:5175-81.
65. Ribera JM, Oriol A, González M, Vidriales B, Brunet S, Esteve J, et al. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. *Haematologica* 2010; 95:87-95.
66. Fuster JL, Bermúdez M, Galera A, Llinares ME, Calle D, Ortuño FJ. Imatinib mesylate in combination with chemotherapy in four children with de novo and

## References

---

- advanced stage Philadelphia chromosome-positive acute lymphoblastic leukemia. *Haematologica* 2007; 92:1723-4.
67. Balduzzi A, Valsecchi MG, Uderzo C, De Lorenzo P, Klingebiel T, Peters C, et al. Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study. *Lancet* 2005; 366:635-42.
68. Paolucci G, Vecchi V, Favre C, Miniero R, Madon E, Pession A, et al. Treatment of childhood acute lymphoblastic leukemia. Long-term results of the AIEOP-ALL 87 study. *Haematologica* 2001; 86:478-84.
69. von der Weid N, Swiss Pediatric Oncology Group (SPOG). Late effects in long-term survivors of ALL in childhood: experiences from the SPOG late effects study. *Swiss Med Wkly* 2001; 131:180-7.
70. Moghrabi A, Levy DE, Asselin B, Barr R, Clavell L, Hurwitz C, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. *Blood* 2007; 109:896-904.
71. Harris MB, Shuster JJ, Pullen DJ, Borowitz MJ, Carroll AJ, Behm FG, et al. Consolidation therapy with antimetabolite-based therapy in standard-risk acute lymphocytic leukemia of childhood: a Pediatric Oncology Group Study. *J Clin Oncol* 1998; 16:2840-7.
72. Lauer SJ, Shuster JJ, Mahoney DH Jr, Winick N, Toledano S, Munoz L, et al. A comparison of early intensive methotrexate/mercaptopurine with early intensive alternating combination chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group phase III randomized trial. *Leukemia* 2001; 15:1038-45.
73. Mörnicke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dördelmann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. *Blood* 2008; 111:4477-89.
74. Vora A, Mitchell CD, Lennard L, Eden TO, Kinsey SE, Lilleyman J, et al. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial. *Lancet* 2006; 368:1339-48.
75. Conter V, Valsecchi MG, Silvestri D, Campbell M, Dibar E, Magyarosy E, et al. Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial. *Lancet* 2007; 369:123-31.

## References

---

76. De Moerloose B, Suciú S, Bertrand Y, Mazingue F, Robert A, Uyttebroeck A, et al. Improved outcome with pulses of vincristine and corticosteroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and lymphoblastic non-Hodgkin lymphoma (NHL): report of the EORTC randomized phase 3 trial 58951. *Blood* 2010; 116:36-44.
77. Paietta E. Assessing minimal residual disease (MRD) in leukemia: a changing definition and concept? *Bone Marrow Transplant* 2002;29(6):459-65.
78. Campana D. Determination of minimal residual disease in leukaemia patients. *Br J Haematol* 2003; 121:823-38.
79. Kerst G, Kreyenberg H, Roth C, Well C, Dietz K, Smith EC, et al. Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR. *Br J Haematol* 2005; 128:774-82.
80. Krampera M, Perbellini O, Vincenzi C, Zampieri F, Pasini A, Scupoli MT, et al. Methodological approach to minimal residual disease detection by flow cytometry in adult B-lineage acute lymphoblastic leukemia. *Haematologica* 2006; 91:1109-12.
81. Campana D. Status of minimal residual disease testing in childhood haematological malignancies. *Br J Haematol* 2008; 143:481-9.
82. Irving J, Jesson J, Virgo P, Case M, Minto L, Eyre L, et al. Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting. *Haematologica* 2009; 94(6):870-4.
83. Dworzak MN. Immunological detection of minimal residual disease in acute lymphoblastic leukemia. *Onkologie* 2001;24(5):442-8.
84. Greig B, Oldaker T, Warzynski M, Wood B. 2006 Bethesda international consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: recommendations for training and education to perform clinical flow cytometry. *Cytometry B Clin Cytom* 2007;72 (Suppl 1):S23-33.
85. Nguyen D, Diamond LW, Braylan RC. *Flow cytometry in hemathopathology: a visual approach to data analysis and interpretation*. 2<sup>nd</sup>ed. Totowa, New Jersey: Humana Press; 2007.
86. O'Gorman MRG, Scholl PR. Role of flow cytometry in the diagnostic evaluation of primary immunodeficiency disease. *Clin Applied Immunol Rev* 2002;2(6):321-35.

## References

---

87. Zweidler-McKay PA, Borowitz MJ. Minimal residual disease in acute lymphoblastic leukemia. In: Advani AS, Lazarus HM (eds). *Adult acute lymphoblastic leukemia: biology and treatment*. 1<sup>st</sup>ed. New York: Springer Science -Business Media; 2011. 45-61.
88. Gökbuğet N, Hoelzer D. Adult acute lymphoblastic leukemia. In: Hoffbrand AV, Catovsky D, Tuddenham EGD (eds). *Postgraduate haematology*. 6<sup>th</sup>ed. Oxford: Blackwell Publishing Ltd; 2011. 433-46.
89. Bene MC, Kaeda JS. How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European Leukaemia Net. *Haematologica* 2009; 94(8): 1135-50.
90. Szczepanski T, Willemse MJ, Brinkhof B, van Wering ER, van der Burg M, van Dongen JJ. Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B-ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease. *Blood* 2002;99(7):2315-23.
91. Rimsza LM, Larson RS, Winter SS, Foucar K, Chong YY, Garner KW, et al. Benign hematogone-rich lymphoid proliferations can be distinguished from B-lineage acute lymphoblastic leukemia by integration of morphology, immunophenotype, adhesion molecule expression and architectural features. *Am J Clin Pathol* 2000; 114: 66-75.
92. McKenna RW, Wasington LT, Aquino DB, Picker LJ, Kroft SH. Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry. *Blood* 2001; 98: 2498-507.
93. Muzzafar T, Medeiros LJ, Wang SA, Brahmandam A, Thomas DA, Jorgensen JL, et al. Aberrant underexpression of CD81 in precursor B-cell acute lymphoblastic leukemia. *Am J Clin Pathol* 2009; 132:692-8.
94. Levy S, Shoham T. The tetraspanin web modulates immune-signaling complexes. *Nat Rev Immunol* 2005;5:136-48.
95. Zoller M. Tetraspanins: push and pull in suppressing and promoting metastasis. *Nat Rev Cancer* 2009; 9:40-55.
96. Vanzelm MC, Smet J, Adams B, Mascart F, Schandené L, Janssen F, et al. CD81 gene defect in humans disrupts CD19 complex formation and leads to antibody deficiency. *J Clin Invest* 2010; 120(4): 1265-74.
97. Levy S, Shoham T. The tetraspanin web modulates immune signaling complexes. *Nat Rev Immunol* 2005; 5(2): 136-48.

## References

---

98. Shoham T, Rajapaksa R, Kuo CC, Haimovich J, Levy S. Building of the tetraspanin web: distinct structural domains of CD81 function in different cellular compartments. *Mol Cell Biol* 2006; 26: 1373-85.
99. Greene JL, Leytze GM, Emswiler J, Peach R, Bajorath J, Cosand W, et al. Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions. *J Biol Chem* 1996; 271: 26762-71.
100. Kapsogeorgou EK, Moutsopoulos HM, Manoussakis MN. Functional expression of a costimulatory B7-2 (CD86) protein of human salivary gland epithelial cells that interacts with the CD28 receptor, but has reduced binding to CTLA-4. *J Immunol* 2001; 166: 3107-13.
101. VanSpruiel AB. Tetraspanins in the humoral immune response. *Biochem Soc Trans* 2011; 39(2):512-7.
102. Tachibana I, Hemler ME. Role of transmembrane 4 superfamily (TM4SF) CD9 and CD81 in muscle cell fusion and myotube maintenance. *J Cell Biol* 1999; 146:893-904.
103. Luo RF, Zhao S, Tibshirani R, Mykilebust JH, Sanyal M, Fernandez R, et al. CD81 protein is expressed at high levels in normal germinal center B cells and in subtypes of human lymphomas. *Human Pathol* 2010; 41(2): 271-80.
104. Bair E, Tibshirani R. Semi-supervised methods to predict patient survival from gene expression data. *PLoS Biol* 2004; 2:1-12.
105. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B cell lymphoma identified by gene expression profiling. *Nature* 2000; 403:503-11.
106. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. Lymphoma/leukemia molecular profiling project. the use of molecular profiling to predict survival after chemotherapy for diffuse large B cell lymphoma. *N Engl J Med* 2002; 346:1937-47.
107. Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TF, et al. Molecular mechanisms in malignant lymphomas network project of the deutsche krebshilfe: a biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. *N Engl J Med* 2006;354:2419-30.
108. Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, Botstein D, et al. Prediction of survival in diffuse large-B cell lymphoma based on the expression of six genes. *N Engl J Med* 2004; 350:1828-37.

## References

---

109. Lossos IS, Morgensztern D. Prognostic biomarkers in diffuse large B cell lymphoma. *J Clin Oncol* 2006; 24: 995-1007.
110. Tsuji K, Feng MA, Wang D. Development of human lymphohematopoiesis defined by CD34 and CD81 expression. *Leuk lymphoma* 2002; 43(12): 2269-73.
111. Paiva B, Gutierrez NC, Chen X, Vidriales MB, Montalban MA, Rosinol L, et al. Clinical significance of CD81 expression by clonal plasma cells in high risk smoldering and symptomatic multiple myeloma patients. *Leukemia* 2012; 26(8): 1862-9.
112. Briggles C, Bain BJ. Basic hematological techniques. In: Bain BJ, Lewis SM, Bates I (eds). *Dacie and Lewis practical hematology*. 11<sup>th</sup>ed. Philadelphia: Churchill Livingstone Elsevier; 2011. 23-56.
113. Lamb JE, Price PC. Kidney function tests. In: Burtis CA, Ashwood ER (eds). *Teitz textbook of clinical chemistry and molecular diagnostics*. 5<sup>th</sup> ed. St Louis: Elsevier Saunders Co; 2012. 669-708.
114. Bates I, Burthem J. Bone marrow biopsy. In: Bain BJ, Lewis SM, Bates I (eds). *Dacie and Lewis practical hematology*. 11<sup>th</sup> ed. Philadelphia: Churchill Livingstone Elsevier; 2011. 123-37.
115. Matutes E, Morilla AR. Immunophenotyping. In: Bain BJ, Lewis SM, Bates I (eds). *Dacie and Lewis practical hematology*. 11<sup>th</sup> ed. Philadelphia: Churchill Livingstone Elsevier; 2011. 353-71.
116. Schick MR, Levy S. The TAPA-1 molecule is associated on the surface of B cells with HLA-DR molecules. *J Immunol* 1993; 151(8): 4090-7.
117. Kotz S, Balakrishnan N, Read CB, Vidakovic B. *Encyclopedia of statistical sciences*. 2<sup>nd</sup>ed. Hoboken, New Jersey: Wiley-Interscience; 2006.
118. Kirkpatrick LA, Feeney BC. *A simple guide to IBM SPSS statistics for version 20.0*. Student ed. Belmont, Calif.: Wadsworth, Cengage Learning; 2013.
119. Tekgündüz E, Demir M, Akpınar S. Acute lymphoblastic leukemia; prognostic factors' perspective. *Uluslararası Hematoloji-Onkoloji Dergisi* 2010;20(1):57-66.
120. Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A, et al. Proposals for the immunological classification of acute leukemias, European Group for the Immunological Characterization of Leukemias (EGIL). *Leukemia* 1995; 9(10): 1783-6.
121. Cobaleda C, Sanchez-Garcia I. B-cell acute lymphoblastic leukaemia: towards understanding its cellular origin. *Bioessays* 2009; 31(6):600-9.

## References

---

122. Onciu M. Acute Lymphoblastic Leukemia. *Hematol Oncol Clin N Am* 2009; 23: 655-74.
123. Dworzak MN, Fröschl G, Printz D, Mann G, Pötschger U, Mühlegger N, et al. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. *Blood* 2002; 99: 1952-8.
124. Xu XJ, Tang YM, Shen HQ, Song H, Yang SL, Shi SW, et al. Day 22 of induction therapy is important for minimal residual disease assessment by flow cytometry in childhood acute lymphoblastic leukemia. *Leuk Res* 2012; 36(8):1022-7.
125. Horvath G, Serru V, Clay D, Billard M, Boucheix C, Rubinstein E. CD19 is linked to the integrin-associated tetraspans CD9, CD81, and CD82. *J Biol Chem* 1998; 273: 30537-43.
126. Moreno-Madrid F, Uberos J, Diaz-Molina M, et al. The presence of precursors of benign pre-B lymphoblasts (Hematogones) in the bone marrow of a pediatric patient with cytomegalovirus infection. *Clin Med Oncol* 2008;2:437-9.
127. Guiziry DE, El GW, Farahat N, Hassab H. Phenotypic analysis of bone marrow lymphocytes from children with acute thrombocytopenic purpura. *Egypt J Immunol* 2005; 12(1):9–14.
128. Hafiz G, Mannan MA. Serum lactate dehydrogenase level in childhood acute lymphoblastic leukemia. *Bangladesh Med Res Counc Bull* 2007; 33: 88-91.
129. Fawzi M, Alwan AF, Fahd HI et al. Serum Lactate Dehydrogenase Level in acute leukemias. *J Fac Med Baghdad* 2007;49(4):369-72.
130. Wenxiu S, Yan C. The characteristics of immunophenotype in acute lymphoblastic leukemia and its clinical significance. *The Chinese-German J Clin Oncol* 2005;4(6):354-7.
131. Barrena S, Almeida J, Yunta M, López A, Fernández-Mosteirín N, Giralt M, et al. Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation. *Leukemia* 2005;19: 1376-83.
132. Sanchez ML, Almeida J, Vidriales B, Lopez-Berges MC, GarciaMarcos MA, Moro MJ, et al. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation. *Leukemia* 2002;16: 1460–9.

## References

---

133. Lucio P, Parreira A, van den Beemd MW, van Lochem EG, van Wering ER, Baars E, et al. Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL. *Leukemia* 1999; 13: 419–27.
134. Vidriales MB, Perez JJ, Lopez-Berges MC, Gutierrez N, Ciudad J, Lucio P, et al. Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value. *Blood* 2003;101: 4695–700.
135. van Lochem EG, Wiegers YM, van den Beemd R, Hählen K, van Dongen JJ, Hooijkaas H. Regeneration pattern of precursor-B-cells in bone marrow of acute lymphoblastic leukemia patients depends on the type of preceding chemotherapy. *Leukemia* 2000;14:688-95.
136. van Wering ER, van der Linden-Schrever BE, Szczepanski T, Willemsse MJ, Baars EA, van Wijngaarde-Schmitz HM, et al. Regenerating normal B-cell precursors during and after treatment of acute lymphoblastic leukaemia: implications for monitoring of minimal residual disease. *Br J Haematol* 2000;110:139-46.
137. Borowitz MJ, Pullen DJ, Winick N, Martin PL, Bowman WP, Camitta B. Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: implications for residual disease detection: a report from the Children's Oncology Group. *Cytometry B Clin Cytom* 2005;68:18-24.
138. Chen W, Karandikar NJ, McKenna RW, Kroft SH. Stability of leukemia-associated immunophenotypes in precursor B-lymphoblastic leukemia/lymphoma: a single institution experience. *Am J Clin Pathol* 2007;127:39-46.

## المخلص العربي

سرطان الدم الليمفاوى الحاد هو مرض نسيلى خبيث للنسيج الدموى ينشأ فى خلية ليمفاوية سلفية واحدة بى أو تى، وهذا يؤدى إلى تكاثر وتراكم الخلايا السرطانية فى النخاع العظمى، مما يؤدى إلى تثبيط تكون الدم وخلل فى توزيع خلايا النخاع العظمى ثم تظهر هذه الخلايا السرطانية (الليمفوبلاست) فى الدم. يمثل سرطان الدم الليمفاوى الحاد حوالى ٨٠% من اللوكيميا الحادة بينما يمثل سرطان الدم الليمفاوى بى ٨٥% من سرطان الدم الليمفاوى الحاد. تظهر ذروة المرض فى الأطفال ما بين سنتين حتى خمس سنوات خاصة فى الذكور.

تتضمن الطرق التقليدية لتشخيص سرطان الدم الليمفاوى الحاد فحص الدم ، فحص النخاع العظمى والتصنيف الظاهرى المناعى عن طريق التدفق الخلوى الذى يتميز بقدرته على التشخيص المبدئى للمرض بالإضافة إلى الكشف عن الحد الأدنى المتبقى للمرض وذلك لأنه يتميز بالسرعة والحساسية والتقدير الكمى. الحد الأدنى المتبقى للمرض هو أقل حد قابل للاكتشاف من المرض المتبقى فى مرحلة الشفاء الاكلينيكي التام الذى يمكن أن يكتشف فقط بوسائل شديدة الحساسية مثل التدفق الخلوى أو تفاعل البلمرة المتسلسل ويعتبر الحد الأدنى المتبقى للمرض مؤشرا رئيسيا لانتكاس اللوكيميا.

الصعوبة الأساسية فى تقدير الحد الأدنى المتبقى للمرض تكمن فى الحالات التى لديها كرات دموية بدائية حميدة ب (هيماتوجون) بكثرة فى النخاع العظمى وخاصة فى الأطفال بعد علاج سرطان الدم الليمفاوى الحاد. و تكمن الصعوبة فى التشابه القريب بين الهيماتوجون والليمفوبلاست فى الشكل والنمط الظاهرى المناعى.

حيث أن الليمفوبلاست تتميز باكتساب أو فقد مستضدات أو تغير فى شكل أو كثافة تمثيل هذه المستضدات على سطحها، مما يعطيهما نمط ظاهرى مناعى مميز عن الخلايا الطبيعية، فالدلالة المثالية التى تقاس بواسطة التدفق الخلوى لاكتشاف الحد الأدنى المتبقى للمرض لابد أن يكون لديها شكل ثابت على الهيماتوجون وشكل مختلف على الليمفوبلاست، حتى يتم التفرقة بينهم بوضوح، مع أهمية أن يكون مستوى هذه الدلالة على الليمفوبلاست ثابت مع الوقت حتى تتم المتابعة من خلالها بعد العلاج.

سى دى ٨١ المعروف باسم (تابا-١) هو عضو فى عائلة التتراسباتين، يوجد على معظم الأنسجة البشرية فيما عدا كرات الدم الحمراء والصفائح الدموية. و هو يكون المركب المتعدد الجزينات ( سى دى ١٩- سى دى ٢١ - سى دى ٨١) الذى يشترك فى تنظيم الإشارات فى الخلايا الليمفاوية ب.

إن الهدف الاساسى من هذا العمل هو دراسة تعبير السى دى ٨١ على الليمفوبلاست فى حالات سرطان الدم الليمفاوى الحاد ب ومقارنته بالهيماتوجون مع تقييم فائدته فى اكتشاف الحد الأدنى المتبقى للمرض عن طريق جهاز التدفق الخلوى فى حالات سرطان الدم الليمفاوى الحاد ب فى الأطفال و قد أجريت الدراسة الحالية على ٣٢ مريض من الذين تم تشخيصهم حديثا بمرض سرطان الدم الليمفاوى الحاد ب ومتابعتهم بعد ٢٨ يوم من بدء العلاج و ٣٢ مريض متناظرين فى العمر والجنس كمجموعة تقييم يتميزوا بزيادة فى الهيماتوجون فى النخاع العظمى نتيجة لأمراض أخرى، و قد تم اختيار الحالات على أساس التشخيص المبدئى من ناحية الصفات الاكلينيكية وشكل الخلايا و النمط الظاهرى المناعى.

تم تقدير متوسط كثافة الوميض للسى دى ٨١ عن طريق جهاز التدفق الخلوى فى المجموعة الأولى عند التشخيص وبعد ٢٨ يوم من بدء العلاج لاختبار فائدة سى دى ٨١ فى الكشف عن الحد الأدنى المتبقى للمرض، كذلك تم تقديره فى المجموعة الثانية لكن عند التشخيص فقط، كما تم مقارنته فى أنواع سرطان الدم الليمفاوى الحاد ب الفرعية المختلفة. وكان متوسط كثافة الوميض للسى دى ٨١ أقل فى الليمفوبلاست فى حالات سرطان الدم الليمفاوى الحاد ب بينما كان مرتفع فى الهيماتوجون فى مجموعة التقييم وقد أظهر فرق ذو دلالة احصائية بين المجموعتين (باحتمال أقل من ٠,٠٠١).

جميع الحالات ما عدا حالتين (وفاة) كانوا فى مرحلة شفاء تام بعد ٢٨ يوم من بدء العلاج ولم يوجد حد الأدنى المتبقى للمرض بالطريقة التقليدية للكشف عنه ولكن معظمهم أظهروا هيماتوجون فى النخاع العظمى. متوسط كثافة الوميض للسى دى ٨١ فى هذه الحالات كان مرتفع مما أكد نتائج الطريقة التقليدية.

تم متابعة حالتين بعد ٢٨ يوم لأنهم أظهروا انتكاسة للمرض وقد أظهروا أيضا متوسط كثافة الوميض للسى دي ٨١ منخفض مماثل لما كانت عليه عند التشخيص مما أظهر ثبات تعبير السى دي ٨١ على الليمفوبلاست قبل وبعد العلاج. وقد أظهر تقييم متوسط كثافة الوميض للسى دي ٨١ بين أنواع سرطان الدم الليمفاوى الحاد ب الفرعية المختلفة فروق ذات دلالة احصائية (باحتمال أقل من ٠,٠٠١) حيث أظهر النوع المسمى بسرطان الدم الليمفاوى الحاد ب المشترك أقل قيمة لمتوسط كثافة الوميض للسى دي ٨١ .

تقييم منحى الروك أظهر قيمة رقمية قطعية لمتوسط كثافة الوميض للسى دي ٨١ وهى ١١٣٤ تتيح التفرقة بين الليمفوبلاست فى حالات سرطان الدم الليمفاوى الحاد ب ( $\geq 1134$ ) والهيماتوجون فى حالات التقييم ( $< 1134$ ) بأعلى مستوى من الحساسية و الخصوصية.



جامعة الإسكندرية  
كلية الطب  
قسم الباثولوجيا الإكلينيكية والكيميائية

قيمة إظهار سى دى ٨١ فى الكشف عن الحد الأدنى المتبقى من مرض  
سرطان الدم الليمفاوى الحاد ب عند الأطفال بواسطة استخدام جهاز التدفق  
الخلوى

رسالة مقدمة

لقسم الباثولوجيا الإكلينيكية والكيميائية - كلية الطب - جامعة الإسكندرية  
ضمن متطلبات درجة

الماجستير

فى

الباثولوجيا الإكلينيكية والكيميائية

من

داليا محمد طارق محمد جلال فرغلى

بكالوريوس الطب والجراحة، ٢٠٠٧

كلية الطب، جامعة الإسكندرية

طبيب مقيم بقسم أمراض الدم- معهد البحوث الطبية

[٢٠١٥]



جامعة الإسكندرية  
كلية الطب  
قسم الباثولوجيا الإكلينيكية والكيميائية

قيمة إظهار سى دى ٨١ فى الكشف عن الحد الأدنى المتبقى من مرض  
سرطان الدم الليمفاوى الحاد ب عند الأطفال بواسطة استخدام جهاز التدفق  
الخلوى

رسالة مقدمة من

داليا محمد طارق محمد جلال فرغلى

للحصول على درجة

الماجستير

فى

الباثولوجيا الإكلينيكية والكيميائية

التوقيع

.....

.....

.....

لجنة المناقشة والحكم على الرسالة

أ.د/ نادية على صادق

أستاذ أمراض الدم

قسم أمراض الدم

معهد البحوث الطبية

جامعة الإسكندرية

أ.د/ نهلة محمد جمال فرحات

أستاذ الباثولوجيا الإكلينيكية والكيميائية

قسم الباثولوجيا الإكلينيكية والكيميائية

كلية الطب

جامعة الإسكندرية

أ.د/ مجدى ممدوح البردينى

أستاذ الباثولوجيا الإكلينيكية والكيميائية

قسم الباثولوجيا الإكلينيكية والكيميائية

كلية الطب

جامعة الإسكندرية

## لجنة الإشراف

## موافقون

أ.د/ نهلة محمد جمال فرحات

أستاذ الباثولوجيا الإكلينيكية والكيميائية  
قسم الباثولوجيا الإكلينيكية والكيميائية  
كلية الطب  
جامعة الإسكندرية

أ.د/ ماجدة محمد سلطان

أستاذ أمراض الدم  
قسم أمراض الدم  
معهد البحوث الطبية  
جامعة الإسكندرية

د/ احمد محمد لطفى بديوى

مدرس أمراض الدم  
قسم أمراض الدم  
معهد البحوث الطبية  
جامعة الإسكندرية

د/ هناء محمود دنيا

مدرس الباثولوجيا الإكلينيكية والكيميائية  
قسم الباثولوجيا الإكلينيكية والكيميائية  
كلية الطب  
جامعة الإسكندرية